Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.
Cipla: Omeprazole exports hold the key - Views on News from Equitymaster
A 20.7% growth in the topline for Cipla has led to an identical growth in the bottomline. While the result is quite creditable the fact remains that the operating margins are under pressure having come down by 1.7%.
(Rs m)
1QFY00
1QFY01
Change
Sales
2,004
2,418
20.7%
Other Income
51
76
48.6%
Expenditure
1,565
1,929
23.3%
Operating Profit (EBDIT)
439
489
11.4%
Operating Profit Margin (%)
21.9%
20.2%
Interest
3
4
Depreciation
35
38
7.1%
Profit before Tax
452
523
15.8%
Other Adjustments
Tax
130
135
Profit after Tax/(Loss)
322
388
20.7%
Net profit margin (%)
16.0%
16.0%
No. of Shares (m) (eoy)
20.0
60.0
Diluted no. of shares (m)
60.0
60.0
Diluted Earnings per share*
21.4
25.9
*(annualised)
The growth in the profits has been maintained by other income which is almost 20% of the pre–tax profits as against 15% in the previous year and by a lower effective tax rate of 25.8% as against 28.7% in the first quarter of last year.
What is critical to sustain Cipla's growth in the future is omeprazole exports to the USA which are dependent on whether Astra Zeneca which holds the patent for 'Prilosec' gets a patent extension due to 'Nexia' its new generation anti–ulcer drug.
Also the fate of exports of its anti–AIDS formulation to South Africa still hangs in the balance as compulsory licensing is unlikely to be introduced since international patent holders such as Glaxo and Boehringer Mannheim are planning to offer discounts on their patented treatments.
The stock quotes at Rs 712 which implies an earning multiple of 27.5 times of the FY2001 annualised earnings.
Equitymaster requests your view! Post a comment on "Cipla: Omeprazole exports hold the key". Click here!
Thank you for posting your view on Equitymaster!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!
Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.
Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
Equitymaster requests your view! Post a comment on "Cipla: Omeprazole exports hold the key". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!